IMAGION BIOSYSTEMS LIMITED (IBX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
IBX - IMAGION BIOSYSTEMS LIMITED
FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.35
30 Nov |
OPEN $0.34 |
HIGH $0.39 |
26,188 LOW $0.34 |
0.010FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -35.0 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.5 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 16.7 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -8.1 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -2,071.53 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -109.07 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -90.90 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -81.42 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -109.07 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -108.06 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -8.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 5 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 4 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 5.75 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.5 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 107.16 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | - |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 12 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 4 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
0.0
No. Of Recommendations
0
IBX STOCK CHART
FNArena News on IBX
| 1 |
Dr Boreham’s Crucible: Imagion BiosystemsFeb 13 2023 - Small Caps |
| 2 |
Who Will Be The Next Pro Medicus?May 13 2021 - Weekly Reports |
| 3 |
RESEARCH: Imagion Biosystems, Strong Financing In Place To Support Execution StrategyJul 01 2020 - FYI |
| 4 |
RESEARCH: Innovative Medical Device Company, Imagion BiosystemsSep 27 2019 - FYI |
| 5 |
RESEARCH: Interview Bob Proulx, CEO Imagion BiosystemsSep 18 2019 - FYI |
